遗传变异对酒精性肝病的影响

肝脏 ›› 2022, Vol. 27 ›› Issue (4): 389-390.

遗传变异对酒精性肝病的影响

柳涛, 刘雅丽, 肖鹏, 高沿航

130021 长春吉林大学第一医院肝胆胰内科

收稿日期:2022-03-25 出版日期:2022-04-30 发布日期:2022-06-02
通讯作者: 高沿航,Email:yanhang@mail.jlu.edu.cn
基金资助:
国家自然科学基金课题(81972265,82170602)

Received:2022-03-25 Online:2022-04-30 Published:2022-06-02

摘要/Abstract

摘要： 酒精性肝病(ALD)是临床最常见的慢性肝病之一,其发病率与死亡人数逐年上升,给人类社会带来了极大的危害。ALD具体发病机制尚未阐明,但遗传因素在ALD的发生与发展中占有重要作用,本文就此领域进展做详细总结。

关键词: 酒精性肝病, 遗传, 危险因素, 全基因组关联分析

柳涛, 刘雅丽, 肖鹏, 高沿航. 遗传变异对酒精性肝病的影响[J]. 肝脏, 2022, 27(4): 389-390.

[1] World Health Organization. Global status report on alcohol and health 2018. http://www.who.int/publications/i/item/9789241565639
[2] Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology,2011,141:1572-1585.
[3] Wilfred de Alwis NM, Day CP. Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Semin Liver Dis,2007,27:44-54.
[4] Buch S, Stickel F, Trépo E, et al. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nat Genet, 2015,47:1443-1448.
[5] Stickel F, Hampe J. Genetic determinants of alcoholic liver disease. Gut,2012,61:150-159.
[6] Verhulst B, Neale MC, Kendler KS. The heritability of alcohol use disorders: a meta-analysis of twin and adoption studies. Psychol Med,2015,45:1061-1072.
[7] Kim KY, Kim JO, Kim YS, et al. Genome-wide association of individual vulnerability with alcohol-associated liver disease: A Korean genome and epidemiology study. Hepatology, 2022,75:391-402.
[8] Kim Y, Han BG. Cohort Profile: The Korean Genome and Epidemiology Study (KoGES) Consortium. Int J Epidemiol,2017,46:1350.
[9] Edenberg HJ, McClintick JN. Alcohol Dehydrogenases, Aldehyde Dehydrogenases, and Alcohol Use Disorders: A Critical Review. Alcohol Clin Exp Res,2018,42:2281-2297.
[10] He L, Deng T, Luo HS. Genetic polymorphism in alcohol dehydrogenase 2 (ADH2) gene and alcoholic liver cirrhosis risk. Int J Clin Exp Med, 2015,8:7786-7793.
[11] Piao YF, Li JT, Shi Y. Relationship between genetic polymorphism of cytochrome P450IIE1 and fatty liver. World J Gastroenterol,2003,9:2612-2615.
[12] J?rvel?inen HA, Orpana A, Perola M, et al. Promoter polymorphism of the CD14 endotoxin receptor gene as a risk factor for alcoholic liver disease. Hepatology, 2001,33:1148-53.
[13] Zhao YY, Xiao M, Zhang CL, et al. Associations between the tumor necrosis factor-α gene and interleukin-10 gene polymorphisms and risk of alcoholic liver disease: A meta-analysis. Clin Res Hepatol Gastroenterol,2016,40:428-439.
[14] Goltz D, Hittetiya K, Vössing LM, et al. A?-antitrypsin PiMZ heterozygosity has an independent aggravating effect on liver fibrosis in alcoholic liver disease. Virchows Arch, 2014,465:539-546.
[15] Barabási AL. Network medicine--from obesity to the "diseasome". N Engl J Med, 2007,357:404-407.

遗传变异对酒精性肝病的影响

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	车莹, 黄晓铨, 陈世耀. 用循证观点看待肝硬化门静脉血栓诊治中的争议[J]. 肝脏, 2022, 27(3): 261-263.
[2]	杜迪, 张宇迪, 刘彦. 重症酒精性肝病合并巨细胞病毒感染1例[J]. 肝脏, 2022, 27(2): 250-251.
[3]	孟方园, 孙悦, 苑广菲, 高沿航. 噬菌体在酒精性肝病治疗中的应用进展[J]. 肝脏, 2021, 26(9): 956-957.
[4]	陈姣艳, 陈斌, 曹冬容, 朱蔓然, 焦志勇, 秦永军, 夏悯馨. 慢性乙型肝炎并发肝衰竭死亡危险因素的研究[J]. 肝脏, 2021, 26(9): 994-997.
[5]	周静, 刘玉姣, 高园, 谷昊. 肝脏切除术后患者发生谵妄危险因素的meta分析[J]. 肝脏, 2021, 26(9): 1031-1035.
[6]	范文瀚, 梁雪松, 陈怡, 廖威, 李成忠. 免疫抑制剂治疗过程中HBV再激活人群危险因素分析[J]. 肝脏, 2021, 26(8): 843-846.
[7]	苑广菲, 孟方园, 阿迪拉·亚克普, 高沿航. 酒精性肝病临床试验的难点与进展[J]. 肝脏, 2021, 26(7): 711-712.
[8]	聂伟杰, 刘家旗, 张锦, 孟存英. ATLI患者遗传易感性及新型生物标志物的研究进展[J]. 肝脏, 2021, 26(7): 807-810.
[9]	杨庆玺, 苏吉亮, 孙忠文, 刘元勋, 胡文娟. 21例肝癌合并脑梗死患者临床特点观察[J]. 肝脏, 2021, 26(6): 642-645.
[10]	商连琴, 岳冬黎, 朱炳喜. 乙型肝炎肝硬化上消化道出血无创性预测模型的建立[J]. 肝脏, 2021, 26(5): 497-501.
[11]	季媛媛, 陈艳清, 程琳, 周海东. 凝血酶原时间是慢性乙型肝炎患者肝活检纤维化程度的独立危险因素[J]. 肝脏, 2021, 26(4): 400-402.
[12]	杜静园, 颜华东. 不同病因肝硬化失代偿患者临床特征及长期预后危险因素的前瞻性队列研究[J]. 肝脏, 2021, 26(2): 140-146.
[13]	陈兴阳, 陈英杰, 陈雷, 张盛. 原发性肝癌根治术后3年生存率与BCLC Kinki分期的关系[J]. 肝脏, 2021, 26(12): 1324-1327.
[14]	周梅月, 全卉, 陈贺宁, 江宇泳. Gao-Binge酒精性肝病模型小鼠的损伤特点[J]. 肝脏, 2021, 26(12): 1407-1410.
[15]	张飞宇, 赵金明, 阿迪拉·亚克普, 高沿航. 全球酒精性肝病的疾病负担及干预策略[J]. 肝脏, 2021, 26(11): 1210-1213.